Grupo Chileno de Estudio de Linfoma retweeted
Epcoritamab + GemOx shows impressive efficacy in transplant-ineligible R/R DLBCL patients per EPCORE NHL-2 Arm 5 trial
🧬💉🩸
•ORR: 85% (CR: 61%)
•1 prior line: ORR 90%, CR 74%
•≥2 lines: ORR 83%, CR 53%
•Median DOCR: 23.6 months
•12-month OS with 1 prior line: 69%
📈⏳🧪
Safety
•Common AEs: cytopenias & CRS
•CRS mostly low-grade, all resolved
⚠️🧠✅
Conclusion:
Deep, durable responses support epcoritamab + GemOx as a promising option in R/R DLBCL ineligible for ASCT
📌🔬🛡️
🔗 Brody et al. Blood 2024; DOI: 10.1182/blood.20240206830
#HemeTwitter #DLBCL #Epcoritamab #CARBTherapy #Lymphoma #BloodCancer #ASCT #Immunotherapy #EPCORE #Hematology #PharmTwitter #OncoTwitter
Grupo Chileno de Estudio de Linfoma retweeted
CLL12 study supports using the watch-and-wait approach as the standard of care for early-stage CLL, including high-risk patients. Ongoin @SWOG S1925 trial evaluates early venetoclax-based treatment for high risk patients. @JCO_ASCO @DebbieMStephens ascopubs.org/doi/full/10.120…
Grupo Chileno de Estudio de Linfoma retweeted
A bright spot 🎇in a meeting full of light was seeing all the connections made at #ASH24.
Who did you meet at the meeting? Tag them below!
Grupo Chileno de Estudio de Linfoma retweeted
Sequencing of therapy for patients with diffuse large B-cell lymphoma in the era of novel drugs - British Journal of Haematology | Wiley Online Library
onlinelibrary.wiley.com/doi/…
Grupo Chileno de Estudio de Linfoma retweeted
Current and upcoming treatment approaches to common subtypes of PTCL (PTCL, NOS; ALCL; and TFHs)
ow.ly/GauQ50TY4CW #lymphoidneoplasia
Grupo Chileno de Estudio de Linfoma retweeted
CONGRESS | #SOHO2024
Christopher Yasenchak, Willamette Valley Cancer Institute, shares results from the phase III ECHELON-3 study of brentuximab vedotin in combination with len and rituximab for R/R DLBCL.
Median PFS 4.2 mo, OS 13.8 mo, ORR 64%, CR 40%, AEs were managed with dose modifications and were consistent with individual known safety profiles.
#lymsm
Grupo Chileno de Estudio de Linfoma retweeted
Results of the phase III SYMPATICO trial presented at #ASCO24 show that ibrutinib + venetoclax is effective for the treatment of pts with MCL & TP35 mutations, with high CR rates & durable remissions 📝
More news: LymphomaHub.com
#lymphoma #MedNews #MedEd @michaelwangmd
A medir y suplementar!! Especialmente acá en Chile , donde el déficit de vitamina d es endémico.
Vitamin D supplement for patients with early-stage chronic lymphocytic leukemia is associated with a longer time to first treatment
ashpublications.org/bloodadv…
4
130
Grupo Chileno de Estudio de Linfoma retweeted
Lymphoma Classifications, How to Develop a Future Unified Taxonomy | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JCO…
Grupo Chileno de Estudio de Linfoma retweeted
Diffuse large B-cell lymphoma at risk of secondary CNS involvement: The inefficacy of IV HD-methotrexate CNS prophylaxis & the importance of baseline cerebrospinal fluid analysis [May 10, 2023] Bennett et al. @AjHematology onlinelibrary.wiley.com/doi/… #lymsm #btsm #CNSprophylaxis
Grupo Chileno de Estudio de Linfoma retweeted
🔴Atrial Fibrillation and Cirrhosis: Which Anticoagulant?
🔹Apixaban might present less bleeding risk than rivaroxaban or warfarin.
🔹Apixaban is associated with a roughly 3-percentage-point lower incidence of bleeding events annually
✔️acpjournals.org/doi/10.7326/…
Grupo Chileno de Estudio de Linfoma retweeted
🖍️Infografías sobre monitorización y ajuste posológico en antifúngicos:
👉Rol de la monitorización en triazólicos
👉Recomendaciones para cada formulación
👉T de muestreo
👉Nivls valle recomendados
👉Ajustes de D en itra, posa, vori e isavuconazol
From:
funguseducationhub.org/funga…
Grupo Chileno de Estudio de Linfoma retweeted
Testing for t(3;8) in MYC/BCL6-rearranged large B-cell lymphoma identifies a high-risk subgroup with inferior survival ashpublications.org/blood/ar…
Grupo Chileno de Estudio de Linfoma retweeted
🚨"Risk of infections with bispecific antibodies in B-cell non-Hodgkin lymphomas and multiple myeloma—The current state.”
The review summarizes @US_FDA Approved BsAb. Work led by PGY1 IM, @AmritGonugunta
@BrJHaem @MDAndersonNews #BiTE #CART #infections
onlinelibrary.wiley.com/doi/… – at West University Place, TX
Grupo Chileno de Estudio de Linfoma retweeted
Good news for follicular lymphoma patients: #epcoritamab receives positive conditional marketing approval from CHMP/EMA based on phase II NHL-1 study results. Another CD20 x CD3 bispecific antibody available
ir.genmab.com/news-releases/…
#lymSM
Grupo Chileno de Estudio de Linfoma retweeted
Clinical Practice Recommendations for Hematopoietic Cell Transplantation and Cellular Therapies in Follicular Lymphoma astctjournal.org/article/S26…
Grupo Chileno de Estudio de Linfoma retweeted
Prepárate para una experiencia de aprendizaje, networking y buena onda en la 2da jornada del GCEL!
26 y 27 de Julio 2024
Double tree by Hilton , av. Kennedy 4422, Vitacura
Únete a nosotros y forma parte del cambio en el tratamiento de los linfomas. ¡No faltes!
Grupo Chileno de Estudio de Linfoma retweeted
Molecular diagnosis of primary CNS lymphoma in 2024 using MYD88Leu265Pro and IL-10 - The Lancet Haematology thelancet.com/journals/lanha…
¡No te pierdas la segunda jornada del Grupo Chileno de Estudio del Linfoma (GCEL)!
Te invitamos a participar de esta imperdible cita que reunirá a algunos de los profesionales más destacados en el estudio y tratamiento del linfoma en Chile y en Latinoamérica.
Fecha: [26 y 27 de Julio]
Horario: [8:30 am ]
Lugar: [Hotel DoubleTree by Hilton. Av. Kennedy Lateral 4422, Vitacura]
¡Inscríbete ya y asegura tu cupo en este importante evento del mundo de la hematología y la oncología! #GCEL #Linfoma #Networking #Hematología
94






































